What is the recommended dosing, administration technique, and monitoring for intralesional triamcinolone in treating localized dermatologic conditions such as hypertrophic scars, keloids, alopecia areata, and granuloma annulare?

Intralesional Triamcinolone: Dosing, Administration, and Monitoring

For localized dermatologic conditions, intralesional triamcinolone acetonide should be dosed at 5-10 mg/mL for alopecia areata and 10-20 mg/mL for keloids and hypertrophic scars, injected just beneath the dermis into the upper subcutis, with 0.05-0.1 mL per injection site producing approximately 0.5 cm diameter of effect. 1, 2

Condition-Specific Dosing

Alopecia Areata

• Concentration: 5-10 mg/mL triamcinolone acetonide (or hydrocortisone acetate 25 mg/mL) 1
• Volume per site: 0.05-0.1 mL produces a tuft of hair growth approximately 0.5 cm in diameter 1
• Frequency: Monthly injections 1
• Best candidates: Patchy hair loss of limited extent (<5 patches, <3 cm diameter), cosmetically sensitive sites like eyebrows 1
• Expected response: 62% achieve full regrowth with monthly injections; effect lasts approximately 9 months 1

Keloids and Hypertrophic Scars

• Concentration: 10-20 mg/mL 2, 3
• Frequency: Every 2-3 weeks 3, 4
• Duration: Continue until lesions flatten or maximum 6 sessions 4
• Intra-articular dosing (for reference): 2.5-5 mg for smaller joints, 5-15 mg for larger joints, up to 40 mg for larger areas 2

Administration Technique

Critical Technical Points

• Depth: Inject just beneath the dermis in the upper subcutis 1
• Site preparation: Shake vial before use to ensure uniform suspension; inspect for clumping or granular appearance (indicates freezing exposure—do not use) 2
• Injection timing: Inject immediately after withdrawal to prevent settling in syringe 2
• Strict aseptic technique is mandatory 2

For Systemic/Intramuscular Use (when indicated)

• Deep gluteal injection required 2
• Minimum 1.5-inch needle for adults; longer needles for obese patients 2
• Avoid subcutaneous injection—causes fat atrophy 2

Alternative Delivery Methods

• Needleless devices (e.g., Dermajet) can be used for alopecia areata
• 62% showed hair regrowth at 12 weeks with three injections using needleless device vs. 7% with saline control 1
• Device must be sterilized between patients 1

Monitoring and Side Effects

Common Adverse Effects by Condition

Alopecia Areata:

• Folliculitis (common with potent topical steroids) 1
• Patient discomfort is the main limitation for multiple injections 1

Keloids/Hypertrophic Scars:

• Hypopigmentation: 55.2% 5
• Skin atrophy: 37-52% 4, 5
• Telangiectasia: 41.4% 5
• These effects are significantly more common than with alternative agents like 5-fluorouracil or bleomycin 4, 6

Critical Safety Considerations

• Avoid blood vessel entry during injection 2
• Avoid tissue surrounding injection site (particularly deltoid region) to prevent tissue atrophy 2
• For tenosynovitis, inject into tendon sheath, NOT tendon substance 2
• If excessive synovial fluid present in joints, aspirate some (but not all) before injection 2

Combination Therapy Considerations

Triamcinolone alone is inferior to combination regimens for keloids and hypertrophic scars. The evidence strongly favors:

• TAC + 5-fluorouracil: Superior efficacy with faster response rates and fewer complications than TAC alone 3, 7, 8

  • Dosing: 0.1 mL of 40 mg/mL TAC + 0.9 mL of 5-FU (50 mg/mL) 7
  • Good-to-excellent improvement: 55% vs. 20% with TAC alone 7

• TAC + 5-FU + pulsed-dye laser: Best patient-reported outcomes (75% good-to-excellent) and superior erythema reduction 7

• Bleomycin monotherapy: More effective than TAC (72% vs. 58% VSS reduction) but causes more pain, ulceration, and hyperpigmentation 9

Practical Algorithm

For Alopecia Areata:

1. Use 5-10 mg/mL concentration
2. Inject 0.05-0.1 mL per 0.5 cm diameter area needed
3. Repeat monthly
4. Limit by patient discomfort tolerance
5. Expect response within 3 weeks, optimal by 9-12 weeks 5

For Keloids/Hypertrophic Scars:

1. First-line: TAC 20 mg/mL + 5-FU 25 mg/mL combination 3, 8
2. Inject every 2-3 weeks
3. Continue until flattening or 6 sessions maximum
4. Monitor for atrophy and telangiectasia at each visit
5. Consider adding pulsed-dye laser for erythema or patient preference 7

Avoid TAC monotherapy for scars—combination therapy demonstrates superior efficacy with better safety profiles, particularly regarding atrophy and telangiectasia 3, 6, 8.